Literature DB >> 22736338

Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection.

Tao Li1, Lun-Xiu Qin, Xiao Gong, Jian Zhou, Hui-Chuan Sun, Shuang-Jian Qiu, Qing-Hai Ye, Lu Wang, Jia Fan.   

Abstract

BACKGROUND: Although the incidence of hepatitis B virus surface antigen (HBsAg)-negative/hepatitis C virus antibody (HCVAb)-negative hepatocellular carcinoma (NBNC-HCC) is gradually increasing, it has been mostly ignored in previous studies. The objective of this exploratory study was to investigate the clinicopathologic characteristics and prognostic factors that influence recurrence and survival in patients with NBNC-HCC.
METHODS: A retrospective analysis was performed of 675 patients with NBNC-HCC and 3529 patients with HBsAg-positive/HCVAb-negative HCC (BNC-HCC) who underwent curative resection between 1997 and 2009. Intrahepatic recurrences were classified into early (≤1 year) and late (>1 year) recurrences. Multivariate competing risks analyses with Bonferroni correction were used to evaluate independent prognostic factors.
RESULTS: There were no significant differences between the NBNC-HCC and BNC-HCC groups regarding overall survival, cumulative incidence of HCC-specific death, and recurrence. However, the patients with NBNC-HCC were much older (P < .001), were associated less often with cirrhosis or elevated α-fetoprotein levels (P < .001), and had a much lower ratio of men to women (P < .001). NBNC-HCC tumors were larger (P < .001), but were involved less often with vascular invasion (P = .004). Women, serum γ-glutamyl transpeptidase level, tumor size, tumor capsule, and tumor differentiation were identified as independent risk factors for HCC-specific survival in patients with NBNC-HCC. The cumulative incidence of HCC-specific death for women with NBNC-HCC was significantly greater than for men with NBNC-HCC (P < .001).Tumor capsule and vascular invasion were identified as independent risk factors for early recurrence of NBNC-HCC, whereas tumor differentiation was identified as the only significant risk factor for late recurrence.
CONCLUSIONS: Patients who had NBNC-HCC had characteristics and prognostic factors that differed from those in patients who had BNC-HCC. Women with NBNC-HCC should be more closely monitored, and it may be worthwhile to evaluate estrogen administration for the maintenance of sex hormone balance and to improve these poor outcomes.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22736338     DOI: 10.1002/cncr.27697

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

1.  Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma.

Authors:  Shan-Shan Wu; Quan-Yuan Shan; Wen-Xuan Xie; Bin Chen; Yang Huang; Yu Guo; Xiao-Yan Xie; Ming-De Lu; Bao-Gang Peng; Ming Kuang; Shun-Li Shen; Wei Wang
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

2.  Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis.

Authors:  Zhao-Ru Dong; Peng-Fei Zhang; Cheng-Hao Wang; Chi Zhang; Jia-Bin Cai; Guo-Ming Shi; Ai-Wu Ke; Hui-Chuan Sun; Shuang-Jian Qiu; Jian Zhou; Jia Fan
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

3.  Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Authors:  Yoshihiro Mikuriya; Hirotaka Tashiro; Tsuyoshi Kobayashi; Shintaro Kuroda; Tomoyuki Abe; Masakazu Hashimoto; Hideki Ohdan
Journal:  Langenbecks Arch Surg       Date:  2015-03-06       Impact factor: 3.445

4.  Clinicopathological characteristics of hepatitis B surface antigen-negative and hepatitis C antibody-negative hepatocellular carcinoma.

Authors:  Hiroya Iida; Tsukasa Aihara; Shinichi Ikuta; Naoki Yamanaka
Journal:  Oncol Lett       Date:  2015-08-04       Impact factor: 2.967

5.  Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease.

Authors:  Kerstin Schütte; Jan Bornschein; Stefan Kahl; Ricarda Seidensticker; Jörg Arend; Jens Ricke; Peter Malfertheiner
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

6.  Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.

Authors:  Lan-Qing Yao; Zheng-Liang Chen; Zi-Han Feng; Yong-Kang Diao; Chao Li; Hai-Ying Sun; Jian-Hong Zhong; Ting-Hao Chen; Wei-Min Gu; Ya-Hao Zhou; Wan-Guang Zhang; Hong Wang; Yong-Yi Zeng; Han Wu; Ming-Da Wang; Xin-Fei Xu; Timothy M Pawlik; Wan Yee Lau; Feng Shen; Tian Yang
Journal:  Ann Surg Oncol       Date:  2022-02-22       Impact factor: 5.344

7.  Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study.

Authors:  Zhuangzhuang Zheng; Zijing Liu; Haifeng Zhang; Xiao Guo; Xiaojing Jia; Jianfeng Wang; Lingbin Meng; Ying Xin; Xin Jiang
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

8.  Alpha-fetoprotein: a controversial prognostic biomarker for small hepatocellular carcinoma.

Authors:  Mohamed Asrih; Sébastien Lenglet; François Mach; Fabrizio Montecucco
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

9.  Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis.

Authors:  Kai-Xuan Liu; Jian-Guo Hong; Rui Wu; Zhao-Ru Dong; Ya-Fei Yang; Yu-Chuan Yan; Chun-Cheng Yang; Lun-Jie Yan; Sheng-Yu Yao; Hai-Chao Li; Xu-Ting Zhi; Tao Li
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

10.  RECK expression is associated with angiogenesis and immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and is a prognostic factor for better survival.

Authors:  Zhao-Ru Dong; Zhi-Qiang Chen; Xiao-Yun Yang; Zi-Niu Ding; Kai-Xuan Liu; Lun-Jie Yan; Guang-Xiao Meng; Ya-Fei Yang; Yu-Chuan Yan; Sheng-Yu Yao; Chun-Cheng Yang; Xu-Ting Zhi; Tao Li
Journal:  J Cancer       Date:  2021-05-05       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.